Compass Group PLC Sponsored ADR (CMPGY)
Compass Pathways: Imminent Commercialization Should Provide Further Upside
Compass Pathways is nearing an inflection point, with solid Phase III data and government support pointing towards a likely FDA approval. CMPS is positioned to address the large, underserved treatment-resistant depression market, leveraging regulatory tailwinds and growing psychiatric support for psychedelics. COMP360's rapid onset and durability should see it become an important option for TRD patients.
Compass Pathways shares rise on Q1 results, accelerated FDA review
Compass Pathways (NASDAQ:CMPS) shares rose 14% after it reported first quarter results that topped expectations and showed continued regulatory progress for its lead therapy COMP360 in treatment-resistant depression. For the quarter, Compass reported an adjusted loss of $0.30 per share, coming in ahead of analyst expectations of a loss per share of $0.43.
Compass Pathways Q1 Earnings Call Highlights
Compass Pathways NASDAQ: CMPS said it has begun a rolling New Drug Application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, and is preparing for a potential launch by the end of the year if the therapy is approved.
Compass Group PLC (CMPGY) Q2 2026 Earnings Call Transcript
Compass Group PLC (CMPGY) Q2 2026 Earnings Call Transcript
Compass Group Q2 Earnings Call Highlights
Compass Group LON: CPG raised its full-year profit outlook after reporting what management described as “another very strong half,” with operating profit up 12% and organic revenue growth a little above 7%.
Compass Minerals International Q2 Earnings Call Highlights
Compass Minerals International NYSE: CMP reported improved profitability in its fiscal second quarter despite lower revenue, as management pointed to stronger margins, progress in its Plant Nutrition business and a major debt reduction milestone.
Compass Diversified Q1 Earnings Call Highlights
Compass Diversified NYSE: CODI reported first-quarter 2026 results that management characterized as a period of execution, highlighted by a divestiture, debt reduction and growth in subsidiary adjusted EBITDA despite macroeconomic uncertainty.
Compass, Inc. (COMP) Q1 2026 Earnings Call Transcript
Compass, Inc. (COMP) Q1 2026 Earnings Call Transcript
Compass, Inc. (COMP) Q1 Earnings and Revenues Top Estimates
Compass, Inc. (COMP) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.17 per share. This compares to a loss of $0.05 per share a year ago.
Compass, Inc. (COMP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Compass (COMP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Compass Minerals: Pittsburgh's Ice Reveals The Value Chain
Compass Minerals holds structural advantages in salt production, with irreplaceable assets and geographic reach supporting a premium market position. Loss of the SHACOG contract impacts only about 1% of CMP's total volumes, with the company prioritizing value over volume in its strategic outlook. Industry dynamics have shifted favorably for CMP after Cargill's exit, depleted inventories, and early bid season price increases, supporting higher EBITDA potential.
Compass Pathways: Red Hot Psychedelic Market For Pioneer With Near Term Psychedelic Filing In TRD
Compass Pathways plc (CMPS) has faced significant risks since my last 'Buy' rating in January 2026. CMPS shares had declined approximately 10% over the intervening months, but then registered huge gains in three market days after White House announcement. The investment thesis previously emphasized exciting prospects, but risk factors had dominated recent performance prior to White House action.
